Vigmed announces first sales of the CLiP® Neo and CLiP® Ven Winged catheters
Following the announcement in June regarding first sales of the patented CLiP® Ported, Vigmed announces their first sales of two more patented product lines: CLiP® Neo and CLiP® Ven Winged. Assembly lines of all three versions are now running, while a ramp-up process is in progress. Additionally a first hospital tender has been won following the first sales activity.
“Winning hospital tenders is normally a long process and the CODAN TRIPLUS success after an unusually short period of time is a strong indication that our products appeal to the market needs”, says Mike Dooley, Vigmed Sales Director Europe. “This bodes well for the upcoming release in other European countries”, he continues.
The product lines already released are to be followed by additional launches from new innovation platforms later in the year.
“Following a two year development, automation and preparation phase, it is satisfying to enter the phase of commercialization and get instant positive feedback from the market”, comments Finn Ketler, Vigmed CEO
For further information contact:
CEO, Finn Ketler 46 42 600 5311 or Sales Director Europe, Mike Dooley 46 42 600 5317
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.
Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor
Tags: